Related Experiment Video
Updated: Oct 23, 2025

Seven Steps to Stellate Cells
Published on: May 10, 2011
Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis
Fangming Yang1, Heng Li2, Yanmin Li1
1Department of Digestive Diseases, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Abstract:
Hepatic fibrosis represents as a dynamic pathological process characterized by the net accumulation of extracellular matrix in the progression of various chronic liver diseases, including viral hepatitis, alcoholic liver disease, and metabolic associated fatty liver disease (MAFLD). Activation of hepatic stellate cells (HSCs) is well-defined to play a central role in the initiation and progression of hepatic fibrosis. However, the activation of HSCs is affected by the complicated microenvironments in liver, which largely attributes to the communication between hepatocytes and multiple tissue-resident cells, including sinusoidal endothelial cells, bile duct epithelial cells, platelets, T cells, B cells, macrophages, natural killer cells, neutrophils, dendritic cells, in the direct or indirect mechanisms. Cellular crosstalk between HSCs and surrounding cells contributes to the activation of HSCs and the progression of hepatic fibrosis. Currently, accumulating evidence have proven the complexity and plasticity of HSCs activation, and further clarification of cellular communication between HSCs and surrounding cells will provide sufficient clue to the development of novel diagnostic methods and therapeutic strategies for hepatic fibrosis.
More Related Videos
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
Introduction to Fibroblasts
Regulation of Hematopoietic Stem Cells
Multipotency of Hematopoietic Stem Cells
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

